These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
23. The Food and Drug Administration and patent law at a crossroads: the listing of polymorph patents as a barrier to generic drug entry. Srivastava D Food Drug Law J; 2004; 59(2):339-54. PubMed ID: 15298015 [No Abstract] [Full Text] [Related]
25. Differentiating low-molecular-weight heparins based on chemical, biological, and pharmacologic properties: implications for the development of generic versions of low-molecular-weight heparins. Jeske WP; Walenga JM; Hoppensteadt DA; Vandenberg C; Brubaker A; Adiguzel C; Bakhos M; Fareed J Semin Thromb Hemost; 2008 Feb; 34(1):74-85. PubMed ID: 18393144 [TBL] [Abstract][Full Text] [Related]
26. Status of generic substitution: problematic drug classes reviewed. Ross MB Hosp Formul; 1989 Aug; 24(8):441-4, 447-9. PubMed ID: 10294356 [TBL] [Abstract][Full Text] [Related]
27. Making all clinical trials available for review: any impact on clinical decisions? Smith GH J Am Pharm Assoc (2003); 2005; 45(1):7-8. PubMed ID: 15730109 [No Abstract] [Full Text] [Related]
28. Enforcement of the current good manufacturing practices for solid oral dosage forms after United States v. Barr Laboratories. Jimenez FA Food Drug Law J; 1997; 52(1):67-82. PubMed ID: 10346711 [No Abstract] [Full Text] [Related]
30. FDA issues requirement for retaining drug samples. Oncology (Williston Park); 1991 May; 5(5):176. PubMed ID: 1832001 [No Abstract] [Full Text] [Related]
31. Food and Drug Administration Modernization Act of 1997; list of documents issued by the Food and Drug Administration that apply to medical devices regulated by the Center for Biologics Evaluation and Research. Food and Drug Administration, HHS. Notice. Fed Regist; 1999 Apr; 64(79):20312-3. PubMed ID: 10558481 [TBL] [Abstract][Full Text] [Related]
34. The significance of pharmacodynamic measurements in the assessment of bioavailability and bioequivalence of psychotropic drugs using CEEG and dynamic brain mapping. Itil TM; Itil KZ J Clin Psychiatry; 1986 Sep; 47 Suppl():20-7. PubMed ID: 3528132 [TBL] [Abstract][Full Text] [Related]
35. [Clinical drug testing in the United States]. Engelbart S Fortschr Med; 1983 Jun; 101(22):1021-2, 1049. PubMed ID: 6347848 [No Abstract] [Full Text] [Related]
36. Prescriptions enter the political arena. Regier H J Leg Med (N Y); 1974; 2(2):24-30. PubMed ID: 4545342 [No Abstract] [Full Text] [Related]
37. Testing of controlled-release transdermal dosage forms. Product development and clinical trials. Shaw JE; Prevo ME; Amkraut AA Arch Dermatol; 1987 Nov; 123(11):1548-56. PubMed ID: 2960274 [TBL] [Abstract][Full Text] [Related]
38. Generic drug purchasing. Mehl B Hosp Pharm; 1988 Feb; 23(2):162-4 contd. PubMed ID: 10286432 [No Abstract] [Full Text] [Related]
39. Additional generics on the market. FDA Drug Bull; 1986 Nov; 16(2):14-5. PubMed ID: 3817341 [No Abstract] [Full Text] [Related]